|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent progression of DKD and may decrease albuminuria.
|
31194487 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The anti-DN benefit of vitamin D can be enhanced when administrated in combination with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
|
30287151 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Away from conventional tactic, a recent report revealed the renoprotective potential of NEPi and angiotensin-converting enzyme (ACE2) activator combination therapy against diabetic nephropathy.
|
31470292 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy.
|
31205872 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Non-DHP CCBs may be a reasonable therapeutic option for patients with diabetic kidney disease and persistent proteinuria despite maximum doses of ACE inhibitors or ARBs.
|
30966785 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
|
31543149 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hypertension and albuminuria may herald diabetic nephropathy and require management with angiotensin converting enzyme (ACE) inhibition.
|
31384418 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
To examine the relative contributions of each ACE domain to the sodium retentive state, renal inflammation, and renal injury associated with diabetic kidney disease, we used streptozotocin to induce diabetes in wild-type mice and in genetic mouse models lacking either a functional ACE N-domain (NKO mice) or C-domain (CKO mice).
|
30185469 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that the intake of linolenic acid was negatively associated with DKD (OR = 0.57; 95% CI 0.35-0.93; P = 0.024), adjusted for gender, smoking, cardiovascular disease, ACE inhibitors and/or angiotensin receptor blocker use, systolic blood pressure, fasting plasma glucose and HDL cholesterol.
|
30092058 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The most common potential omissions at the admission were beta-blockers in cases of stable chronic angina, and angiotensin converting enzyme inhibitors or angiotensin receptor blockers in cases of diabetic nephropathy or renal dysfunction.
|
30242588 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, combination of a bioflavonoid with an Angiotensin converting enzyme (ACE) inhibitor administration restored the antioxidant status in experimental DN rats.
|
30372836 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
|
29185789 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This work increases the understanding of the sex-specific role of ACE2 and ACE in DN, reinforcing the necessity of more personalized treatments targeting RAS.
|
29884907 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have become standards of care for diabetic nephropathy.
|
28177196 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
We compared the renal effects of the (pro)renin receptor ((P)RR) blockade and angiotensin converting enzyme (ACE) inhibition on the progression of diabetic nephropathy in rats.
|
28359068 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We provide first evidence indicating the causation between ACE DD or B2R+9bp genotype and the increased risk for diabetic nephropathy, broadening our horizon about the role of genetic modulators in this disease.
|
28390948 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prompted by the prominent role of angiotensin converting enzyme (ACE) in hypertension, heart failures, myocardial infarction and diabetic nephropathy, we have attempted to discover novel ACE inhibitors through ligand-based virtual screening.
|
28712707 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
After adjustment for clinical covariates, AOG, CTSD, ACE concentration, and ACE activity remained associated with DKD.
|
28468961 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression and dysfunction of adiponectin and the cognate receptors are involved in diabetes and diabetic kidney disease (DKD), whereas angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) alleviate diabetic albuminuria and prevent development of DKD through upregulation of adiponectin expression.
|
28870804 |
2017 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Further, the concomitant study of both systemic and local RAAS, counter-regulators of ACE and ACE2, and also AT1R and angiotensin II type 2 receptor (AT2R) genes could help to elucidate the role of the genes of this system in the pathogenesis of DN.
|
26619914 |
2016 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The association of ACE gene polymorphism with diabetic kidney disease and renoprotective efficacy of valsartan.
|
27638852 |
2016 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis results indicate that the ACE I/D polymorphism may contribute to type 1 DN development, especially in the Asian groups with type 1 diabetes.
|
27498976 |
2016 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results revealed that variations of ACE and eNOS gene had association with DN, which indicated ACE and eNOS gene may play an important role in pathogenesis of DN in Northern Chinese Han population.
|
25227524 |
2015 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Carrying the D-allele of the angiotensin-converting enzyme (ACE) I/D polymorphism and high ACE activity are prognostic factors in diabetic nephropathy, which predicts mortality in type 1 diabetes.
|
23833037 |
2015 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this review, we discuss the relationship between ACE I/D polymorphism and diabetic nephropathy and therapeutic response of RAAS blockers.
|
25587546 |
2014 |